NCT04347252View on ClinicalTrials.gov

Glucagon Regulation of Glucose Metabolism

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Insulin Secretion
Interventions
DRUG

Glucagon

Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.

Trial Locations (1)

27705

Duke Center for Living, Durham

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

David D'Alessio, M.D.

OTHER

NCT04347252 - Glucagon Regulation of Glucose Metabolism | Biotech Hunter | Biotech Hunter